Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Neonc Technologies, Inc.
ImmunityBio, Inc.
Incyte Corporation
Centre hospitalier de l'Université de Montréal (CHUM)
Fate Therapeutics
Jules Bordet Institute
Incyte Corporation
MultiVir, Inc.